193085-19-7

Upstream product

• 147577-61-5 (2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)-propionic acid 
• 193150-11-7 (R)-N-Methyl-2-methylamino-3-phenylpropionamide 
• 193085-18-6 N-Methyl-N-((R)-1-(methylcarbamoyl)-2-phenylethyl)carbamic acid tert-butyl ester 
• 37553-65-4 N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 

Downstream Products

• 186840-95-9 (2R)-N-Methyl-2-methylamino-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)-3-(2-naphthyl)propionamide 
• 193085-20-0 ((3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester 
• 193079-69-5 tabimorelin 

Relevant academic research and scientific papers

Method for preparing a compound with growth hormone releasing properties

A method for preparing a compound of formula I or a salt thereof is disclosed.

Use of growth hormone or a growth hormone secretagogue for promoting bone formation

The invention provides a method of enhancing the healing of bone fractures in an animal subjected to distraction osteogenesis, the method comprising administering, to the animal in need thereof, a growth hormone or a growth hormone secretagogue in an amou

Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide

The compounds disclosed are salts of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide of Formula I which have an aqueous solubility of at least 5 mg/ml, and a

Novel orally active growth hormone secretagogues

A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able t